| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 100 | 2024 | 2592 | 9.100 |
Why?
|
| Shock, Septic | 42 | 2024 | 761 | 5.080 |
Why?
|
| Emergency Service, Hospital | 113 | 2024 | 7818 | 4.610 |
Why?
|
| Microcirculation | 19 | 2024 | 1278 | 3.360 |
Why?
|
| Fluid Therapy | 18 | 2024 | 579 | 3.160 |
Why?
|
| Syncope | 16 | 2019 | 428 | 2.840 |
Why?
|
| Multiple Organ Failure | 12 | 2017 | 386 | 2.780 |
Why?
|
| Hospital Mortality | 61 | 2024 | 5425 | 2.640 |
Why?
|
| Lactic Acid | 18 | 2018 | 1134 | 1.980 |
Why?
|
| Resuscitation | 20 | 2023 | 661 | 1.760 |
Why?
|
| Glycocalyx | 4 | 2024 | 94 | 1.670 |
Why?
|
| Critical Illness | 21 | 2024 | 2709 | 1.520 |
Why?
|
| Systemic Inflammatory Response Syndrome | 13 | 2020 | 621 | 1.490 |
Why?
|
| Prospective Studies | 113 | 2022 | 54303 | 1.200 |
Why?
|
| Hospitalization | 48 | 2024 | 10790 | 1.150 |
Why?
|
| Decision Support Techniques | 9 | 2016 | 2001 | 1.120 |
Why?
|
| Intensive Care Units | 20 | 2021 | 3736 | 1.120 |
Why?
|
| Influenza, Human | 12 | 2024 | 1528 | 1.110 |
Why?
|
| Hypotension | 10 | 2024 | 883 | 1.110 |
Why?
|
| Microscopy, Video | 5 | 2018 | 242 | 1.110 |
Why?
|
| Endothelial Cells | 9 | 2021 | 3539 | 1.100 |
Why?
|
| Influenza Vaccines | 9 | 2024 | 766 | 1.100 |
Why?
|
| Emergency Medicine | 12 | 2021 | 1196 | 1.060 |
Why?
|
| Triage | 12 | 2019 | 987 | 1.030 |
Why?
|
| Shock | 6 | 2020 | 317 | 1.020 |
Why?
|
| Mouth Floor | 8 | 2024 | 38 | 1.000 |
Why?
|
| Heart Arrest | 10 | 2024 | 1506 | 0.940 |
Why?
|
| Severity of Illness Index | 22 | 2022 | 15840 | 0.910 |
Why?
|
| Middle Aged | 181 | 2024 | 220352 | 0.890 |
Why?
|
| Aged | 156 | 2024 | 169152 | 0.870 |
Why?
|
| Bacterial Infections | 2 | 2024 | 1403 | 0.860 |
Why?
|
| Cardiac Output | 3 | 2016 | 838 | 0.860 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 7 | 2019 | 558 | 0.820 |
Why?
|
| Male | 206 | 2024 | 359744 | 0.790 |
Why?
|
| Bacteremia | 5 | 2016 | 980 | 0.790 |
Why?
|
| Health Status Indicators | 5 | 2014 | 968 | 0.780 |
Why?
|
| Oxygen | 17 | 2024 | 4193 | 0.780 |
Why?
|
| Critical Care | 11 | 2023 | 2699 | 0.770 |
Why?
|
| Humans | 298 | 2024 | 760621 | 0.770 |
Why?
|
| Plasma | 1 | 2024 | 584 | 0.740 |
Why?
|
| Vasoconstrictor Agents | 9 | 2023 | 651 | 0.730 |
Why?
|
| Female | 202 | 2024 | 391270 | 0.720 |
Why?
|
| Emergency Medical Services | 7 | 2021 | 1925 | 0.710 |
Why?
|
| Regional Blood Flow | 5 | 2017 | 1490 | 0.700 |
Why?
|
| C-Reactive Protein | 8 | 2022 | 3839 | 0.690 |
Why?
|
| Wounds and Injuries | 6 | 2024 | 2477 | 0.690 |
Why?
|
| Fever | 2 | 2018 | 1617 | 0.690 |
Why?
|
| Risk Assessment | 24 | 2021 | 24123 | 0.670 |
Why?
|
| Outpatients | 5 | 2022 | 1607 | 0.650 |
Why?
|
| Adult | 125 | 2024 | 219994 | 0.640 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2024 | 1004 | 0.640 |
Why?
|
| Blood Coagulation Disorders | 2 | 2020 | 349 | 0.640 |
Why?
|
| Appendicitis | 4 | 2022 | 674 | 0.630 |
Why?
|
| Lipocalins | 2 | 2010 | 161 | 0.630 |
Why?
|
| Thrombelastography | 1 | 2020 | 183 | 0.620 |
Why?
|
| Endothelium, Vascular | 8 | 2024 | 4433 | 0.610 |
Why?
|
| Diabetes Mellitus | 5 | 2017 | 5889 | 0.600 |
Why?
|
| Aged, 80 and over | 57 | 2024 | 58995 | 0.590 |
Why?
|
| Diabetes Complications | 2 | 2017 | 1341 | 0.590 |
Why?
|
| Point-of-Care Systems | 5 | 2014 | 1204 | 0.580 |
Why?
|
| Leukocytes | 3 | 2019 | 2026 | 0.560 |
Why?
|
| Vital Signs | 4 | 2017 | 144 | 0.550 |
Why?
|
| Virus Diseases | 2 | 2024 | 720 | 0.550 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 220 | 0.550 |
Why?
|
| Logistic Models | 24 | 2021 | 13314 | 0.540 |
Why?
|
| Acute Kidney Injury | 5 | 2023 | 1941 | 0.540 |
Why?
|
| Clinical Protocols | 10 | 2024 | 1440 | 0.540 |
Why?
|
| Patient Admission | 7 | 2015 | 1386 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2017 | 1164 | 0.540 |
Why?
|
| Length of Stay | 18 | 2021 | 6479 | 0.540 |
Why?
|
| Predictive Value of Tests | 26 | 2019 | 15289 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 12 | 2022 | 7408 | 0.520 |
Why?
|
| Calcitonin | 1 | 2017 | 330 | 0.520 |
Why?
|
| Comorbidity | 18 | 2019 | 10551 | 0.520 |
Why?
|
| Sensitivity and Specificity | 22 | 2018 | 14660 | 0.500 |
Why?
|
| Emergency Treatment | 6 | 2013 | 498 | 0.490 |
Why?
|
| Endotoxemia | 3 | 2018 | 196 | 0.490 |
Why?
|
| Sodium Chloride | 2 | 2014 | 591 | 0.470 |
Why?
|
| Lactates | 3 | 2013 | 404 | 0.470 |
Why?
|
| Hospital Units | 2 | 2015 | 142 | 0.460 |
Why?
|
| Hospitals, Urban | 8 | 2019 | 499 | 0.450 |
Why?
|
| United States | 61 | 2024 | 72461 | 0.430 |
Why?
|
| Consensus | 5 | 2021 | 3113 | 0.430 |
Why?
|
| Prognosis | 24 | 2024 | 29658 | 0.410 |
Why?
|
| Patient Discharge | 9 | 2021 | 3476 | 0.410 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2024 | 404 | 0.400 |
Why?
|
| Calcium Channel Blockers | 1 | 2015 | 694 | 0.390 |
Why?
|
| Acetylcysteine | 1 | 2013 | 264 | 0.390 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2016 | 741 | 0.390 |
Why?
|
| Patient Positioning | 1 | 2014 | 327 | 0.390 |
Why?
|
| Hospitals, University | 7 | 2016 | 568 | 0.390 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2024 | 448 | 0.390 |
Why?
|
| Protein C | 2 | 2009 | 133 | 0.370 |
Why?
|
| Vitamin D Deficiency | 3 | 2021 | 1379 | 0.370 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 4 | 2013 | 278 | 0.370 |
Why?
|
| Judgment | 2 | 2019 | 273 | 0.370 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 3085 | 0.360 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 3205 | 0.360 |
Why?
|
| Goals | 1 | 2016 | 708 | 0.360 |
Why?
|
| Hyperoxia | 4 | 2018 | 250 | 0.360 |
Why?
|
| Geriatric Assessment | 3 | 2024 | 1405 | 0.360 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 1007 | 0.350 |
Why?
|
| Chest Pain | 7 | 2015 | 1106 | 0.350 |
Why?
|
| Systems Biology | 1 | 2013 | 482 | 0.340 |
Why?
|
| Contrast Media | 2 | 2013 | 5305 | 0.340 |
Why?
|
| Carbon Dioxide | 2 | 2018 | 1146 | 0.340 |
Why?
|
| Critical Pathways | 3 | 2019 | 475 | 0.340 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 1881 | 0.340 |
Why?
|
| Cohort Studies | 35 | 2024 | 41335 | 0.330 |
Why?
|
| Receptor, TIE-2 | 2 | 2021 | 176 | 0.330 |
Why?
|
| Hyperglycemia | 4 | 2012 | 1380 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1259 | 0.330 |
Why?
|
| Leg | 1 | 2014 | 1090 | 0.330 |
Why?
|
| Blood Coagulation Tests | 1 | 2010 | 270 | 0.330 |
Why?
|
| Confidence Intervals | 7 | 2014 | 2932 | 0.320 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 364 | 0.320 |
Why?
|
| Oxygen Consumption | 2 | 2013 | 1843 | 0.320 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2024 | 83 | 0.310 |
Why?
|
| APACHE | 4 | 2017 | 267 | 0.310 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 285 | 0.310 |
Why?
|
| Hydroxychloroquine | 3 | 2022 | 427 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2019 | 20509 | 0.300 |
Why?
|
| Interleukin-1 | 2 | 2009 | 1249 | 0.300 |
Why?
|
| Case-Control Studies | 17 | 2022 | 22053 | 0.300 |
Why?
|
| Erythrocytes | 5 | 2020 | 2415 | 0.300 |
Why?
|
| Acid-Base Equilibrium | 1 | 2008 | 180 | 0.300 |
Why?
|
| Respiration | 1 | 2014 | 1654 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 8950 | 0.300 |
Why?
|
| Dermis | 1 | 2009 | 202 | 0.290 |
Why?
|
| Medical Staff, Hospital | 3 | 2019 | 600 | 0.290 |
Why?
|
| Hypovolemia | 1 | 2007 | 48 | 0.290 |
Why?
|
| Angiopoietin-2 | 6 | 2021 | 172 | 0.290 |
Why?
|
| Dyspnea | 6 | 2015 | 1352 | 0.290 |
Why?
|
| Area Under Curve | 8 | 2018 | 1636 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 4490 | 0.280 |
Why?
|
| Pneumonia | 2 | 2011 | 2131 | 0.280 |
Why?
|
| Appendectomy | 3 | 2022 | 431 | 0.270 |
Why?
|
| Vaccination | 10 | 2024 | 3361 | 0.270 |
Why?
|
| Community-Acquired Infections | 4 | 2020 | 461 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 7475 | 0.270 |
Why?
|
| Monitoring, Physiologic | 4 | 2021 | 1784 | 0.270 |
Why?
|
| Malpractice | 2 | 2023 | 556 | 0.270 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2007 | 113 | 0.270 |
Why?
|
| Cholecalciferol | 2 | 2021 | 550 | 0.250 |
Why?
|
| Inflammation | 5 | 2019 | 10756 | 0.250 |
Why?
|
| Odds Ratio | 9 | 2021 | 9716 | 0.250 |
Why?
|
| Kidney Diseases | 2 | 2013 | 2093 | 0.250 |
Why?
|
| Neoplasms | 8 | 2022 | 22072 | 0.250 |
Why?
|
| Antibodies, Viral | 6 | 2022 | 3143 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 2176 | 0.240 |
Why?
|
| E-Selectin | 3 | 2013 | 576 | 0.240 |
Why?
|
| Insulin | 2 | 2017 | 6597 | 0.240 |
Why?
|
| Risk Factors | 28 | 2020 | 74359 | 0.240 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2019 | 1717 | 0.230 |
Why?
|
| Interleukin-6 | 6 | 2019 | 3215 | 0.230 |
Why?
|
| ROC Curve | 9 | 2017 | 3568 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6544 | 0.230 |
Why?
|
| Chi-Square Distribution | 6 | 2016 | 3465 | 0.230 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 1791 | 0.230 |
Why?
|
| Blood Preservation | 2 | 2016 | 168 | 0.230 |
Why?
|
| Respiration, Artificial | 6 | 2023 | 2622 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2022 | 3484 | 0.220 |
Why?
|
| Patient Transfer | 1 | 2010 | 779 | 0.220 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2011 | 691 | 0.220 |
Why?
|
| Time Factors | 22 | 2023 | 40165 | 0.220 |
Why?
|
| Adenosine Triphosphate | 4 | 2019 | 1993 | 0.220 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2013 | 1126 | 0.210 |
Why?
|
| RNA, Messenger | 9 | 2023 | 12766 | 0.210 |
Why?
|
| Immunocompetence | 2 | 2022 | 138 | 0.210 |
Why?
|
| Communicable Diseases | 2 | 2014 | 878 | 0.210 |
Why?
|
| Multivariate Analysis | 9 | 2014 | 12159 | 0.210 |
Why?
|
| Watchful Waiting | 2 | 2018 | 510 | 0.210 |
Why?
|
| Vaccines, Synthetic | 5 | 2022 | 617 | 0.200 |
Why?
|
| Retrospective Studies | 33 | 2023 | 80372 | 0.200 |
Why?
|
| Enoxaparin | 1 | 2005 | 397 | 0.200 |
Why?
|
| Boston | 8 | 2024 | 9280 | 0.200 |
Why?
|
| Disease Progression | 3 | 2021 | 13502 | 0.200 |
Why?
|
| Leptin | 1 | 2010 | 1591 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2008 | 1724 | 0.200 |
Why?
|
| Age Factors | 11 | 2015 | 18416 | 0.200 |
Why?
|
| Ambulatory Care | 2 | 2020 | 2781 | 0.190 |
Why?
|
| Laryngoscopes | 1 | 2023 | 146 | 0.190 |
Why?
|
| Telemetry | 2 | 2014 | 199 | 0.190 |
Why?
|
| Syndecan-1 | 2 | 2019 | 163 | 0.190 |
Why?
|
| Disease Outbreaks | 2 | 2010 | 1758 | 0.190 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 149 | 0.190 |
Why?
|
| Erythrocyte Transfusion | 3 | 2016 | 566 | 0.180 |
Why?
|
| Unnecessary Procedures | 2 | 2015 | 413 | 0.180 |
Why?
|
| Ritonavir | 1 | 2022 | 328 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 5 | 2015 | 2365 | 0.180 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12531 | 0.180 |
Why?
|
| Protective Agents | 1 | 2021 | 150 | 0.180 |
Why?
|
| Emergencies | 3 | 2021 | 1211 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 4 | 2023 | 1722 | 0.180 |
Why?
|
| Pancreatitis | 2 | 2018 | 1100 | 0.180 |
Why?
|
| Influenza A virus | 1 | 2024 | 457 | 0.180 |
Why?
|
| Telecommunications | 1 | 2020 | 80 | 0.180 |
Why?
|
| Nurse Practitioners | 1 | 2023 | 268 | 0.180 |
Why?
|
| Accidental Falls | 2 | 2019 | 1056 | 0.180 |
Why?
|
| Young Adult | 21 | 2024 | 58741 | 0.170 |
Why?
|
| Oximetry | 2 | 2021 | 461 | 0.170 |
Why?
|
| Appendix | 1 | 2020 | 110 | 0.170 |
Why?
|
| Work | 1 | 2020 | 194 | 0.170 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 368 | 0.160 |
Why?
|
| Intubation, Intratracheal | 2 | 2024 | 1328 | 0.160 |
Why?
|
| Solubility | 3 | 2014 | 1088 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2020 | 238 | 0.160 |
Why?
|
| Diagnosis, Differential | 8 | 2020 | 12965 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 3334 | 0.160 |
Why?
|
| Complement C4b | 2 | 2016 | 132 | 0.160 |
Why?
|
| Flow Cytometry | 4 | 2017 | 5870 | 0.160 |
Why?
|
| Lipopolysaccharides | 3 | 2019 | 2209 | 0.160 |
Why?
|
| Adolescent | 21 | 2024 | 87810 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 926 | 0.160 |
Why?
|
| Iatrogenic Disease | 2 | 2020 | 538 | 0.160 |
Why?
|
| Fractures, Closed | 1 | 2019 | 88 | 0.160 |
Why?
|
| Treatment Outcome | 23 | 2023 | 65017 | 0.160 |
Why?
|
| Age Distribution | 3 | 2014 | 2893 | 0.160 |
Why?
|
| Advisory Committees | 3 | 2021 | 788 | 0.150 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 7806 | 0.150 |
Why?
|
| Acute-Phase Proteins | 2 | 2010 | 250 | 0.150 |
Why?
|
| Receptors, Purinergic | 2 | 2015 | 66 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2021 | 72 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 5508 | 0.150 |
Why?
|
| Contact Tracing | 1 | 2020 | 268 | 0.150 |
Why?
|
| von Willebrand Factor | 2 | 2019 | 673 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2021 | 2283 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2011 | 2809 | 0.150 |
Why?
|
| Pandemics | 10 | 2023 | 8624 | 0.150 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2019 | 151 | 0.150 |
Why?
|
| Rib Fractures | 1 | 2019 | 128 | 0.150 |
Why?
|
| Immunomagnetic Separation | 1 | 2017 | 79 | 0.150 |
Why?
|
| Laryngoscopy | 1 | 2023 | 706 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2012 | 6381 | 0.150 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 1647 | 0.150 |
Why?
|
| Hospital Rapid Response Team | 1 | 2018 | 54 | 0.150 |
Why?
|
| Cytokines | 3 | 2020 | 7343 | 0.150 |
Why?
|
| Carnitine | 1 | 2018 | 252 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 187 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2020 | 1578 | 0.140 |
Why?
|
| Hemodynamics | 8 | 2023 | 4174 | 0.140 |
Why?
|
| Sex Distribution | 3 | 2015 | 2295 | 0.140 |
Why?
|
| Hypercapnia | 1 | 2018 | 261 | 0.140 |
Why?
|
| Patient Selection | 4 | 2013 | 4283 | 0.140 |
Why?
|
| Cell Size | 1 | 2019 | 624 | 0.140 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2020 | 206 | 0.140 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 54 | 0.140 |
Why?
|
| Complement Activation | 2 | 2020 | 446 | 0.140 |
Why?
|
| Acute Disease | 6 | 2022 | 7269 | 0.140 |
Why?
|
| Endothelium | 1 | 2019 | 764 | 0.140 |
Why?
|
| Complement C3a | 1 | 2016 | 66 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2018 | 359 | 0.140 |
Why?
|
| Complement System Proteins | 1 | 2020 | 782 | 0.140 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 345 | 0.140 |
Why?
|
| Morbidity | 2 | 2013 | 1765 | 0.130 |
Why?
|
| Pulmonary Embolism | 4 | 2015 | 2543 | 0.130 |
Why?
|
| Trauma Centers | 3 | 2017 | 933 | 0.130 |
Why?
|
| Denmark | 2 | 2016 | 760 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 780 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2020 | 2648 | 0.130 |
Why?
|
| Blood-Borne Pathogens | 1 | 2016 | 52 | 0.130 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 1933 | 0.130 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 1296 | 0.130 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 247 | 0.130 |
Why?
|
| Anticoagulants | 2 | 2017 | 4897 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2012 | 10182 | 0.130 |
Why?
|
| Mitochondria | 3 | 2019 | 3600 | 0.130 |
Why?
|
| Nitric Oxide | 3 | 2020 | 2141 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 1299 | 0.120 |
Why?
|
| Hypertension | 1 | 2015 | 8594 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1958 | 0.120 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 2754 | 0.120 |
Why?
|
| Angina Pectoris | 3 | 2013 | 969 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2015 | 292 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 1392 | 0.120 |
Why?
|
| Vitamins | 2 | 2021 | 1634 | 0.120 |
Why?
|
| Lipase | 1 | 2017 | 324 | 0.120 |
Why?
|
| International Classification of Diseases | 2 | 2017 | 894 | 0.120 |
Why?
|
| Automation | 1 | 2017 | 580 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 786 | 0.120 |
Why?
|
| Thrombosis | 2 | 2019 | 3052 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2021 | 23376 | 0.120 |
Why?
|
| Placebos | 1 | 2018 | 1668 | 0.120 |
Why?
|
| Troponin I | 4 | 2012 | 638 | 0.120 |
Why?
|
| Lifting | 1 | 2014 | 55 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2016 | 3804 | 0.110 |
Why?
|
| Analgesics | 1 | 2021 | 1065 | 0.110 |
Why?
|
| Calcium Signaling | 2 | 2015 | 732 | 0.110 |
Why?
|
| Stroke Volume | 3 | 2020 | 5523 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 3696 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 563 | 0.110 |
Why?
|
| Blood | 1 | 2016 | 586 | 0.110 |
Why?
|
| Early Diagnosis | 3 | 2021 | 1180 | 0.110 |
Why?
|
| Hypothermia, Induced | 1 | 2018 | 758 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2017 | 1608 | 0.110 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 62 | 0.110 |
Why?
|
| Iodine Compounds | 1 | 2013 | 28 | 0.110 |
Why?
|
| Isotonic Solutions | 1 | 2013 | 116 | 0.110 |
Why?
|
| Glasgow Coma Scale | 3 | 2013 | 579 | 0.110 |
Why?
|
| Acupuncture Therapy | 1 | 2017 | 480 | 0.110 |
Why?
|
| Influenza B virus | 2 | 2024 | 52 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 70 | 0.100 |
Why?
|
| Seasons | 3 | 2024 | 1522 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 2234 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2016 | 5125 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2020 | 2985 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 491 | 0.100 |
Why?
|
| Immunoassay | 1 | 2016 | 746 | 0.100 |
Why?
|
| Mass Screening | 1 | 2008 | 5423 | 0.100 |
Why?
|
| Biological Assay | 1 | 2015 | 630 | 0.100 |
Why?
|
| Patients' Rooms | 2 | 2015 | 62 | 0.100 |
Why?
|
| Observer Variation | 3 | 2014 | 2601 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2116 | 0.100 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2013 | 121 | 0.100 |
Why?
|
| Executive Function | 1 | 2021 | 1374 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2022 | 1150 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2569 | 0.100 |
Why?
|
| Blood Pressure | 6 | 2019 | 8525 | 0.100 |
Why?
|
| Partial Pressure | 3 | 2018 | 245 | 0.100 |
Why?
|
| Terminal Care | 1 | 2024 | 1758 | 0.100 |
Why?
|
| Purines | 1 | 2015 | 605 | 0.100 |
Why?
|
| Medical Records | 2 | 2015 | 1407 | 0.100 |
Why?
|
| Health Status | 4 | 2022 | 4081 | 0.100 |
Why?
|
| Cardiology Service, Hospital | 1 | 2013 | 242 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2019 | 8555 | 0.100 |
Why?
|
| Probability | 4 | 2013 | 2475 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2010 | 1600 | 0.100 |
Why?
|
| Incidence | 10 | 2017 | 21392 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2019 | 1826 | 0.100 |
Why?
|
| Heparin | 1 | 2019 | 1652 | 0.090 |
Why?
|
| Hospitals, Teaching | 2 | 2019 | 1166 | 0.090 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2010 | 17 | 0.090 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2014 | 578 | 0.090 |
Why?
|
| Sound Spectrography | 1 | 2011 | 113 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2019 | 2520 | 0.090 |
Why?
|
| Anemia | 1 | 2020 | 1511 | 0.090 |
Why?
|
| Cellulitis | 1 | 2012 | 207 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2011 | 152 | 0.090 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 681 | 0.090 |
Why?
|
| Creatinine | 2 | 2021 | 1903 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 272 | 0.090 |
Why?
|
| Prevalence | 6 | 2015 | 15687 | 0.090 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2019 | 1066 | 0.090 |
Why?
|
| Troponin | 1 | 2014 | 516 | 0.090 |
Why?
|
| Body Temperature | 2 | 2010 | 777 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 238 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 1377 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 20080 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 2290 | 0.090 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2022 | 350 | 0.090 |
Why?
|
| Coronary Care Units | 1 | 2011 | 235 | 0.090 |
Why?
|
| Syncope, Vasovagal | 1 | 2009 | 38 | 0.080 |
Why?
|
| Clinical Competence | 3 | 2019 | 4783 | 0.080 |
Why?
|
| Survival Rate | 5 | 2017 | 12808 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2017 | 2608 | 0.080 |
Why?
|
| Follow-Up Studies | 8 | 2016 | 39261 | 0.080 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5325 | 0.080 |
Why?
|
| Serpin E2 | 1 | 2009 | 48 | 0.080 |
Why?
|
| Mice, Obese | 1 | 2010 | 420 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 10181 | 0.080 |
Why?
|
| Acid-Base Imbalance | 1 | 2009 | 41 | 0.080 |
Why?
|
| Wounds, Stab | 1 | 2009 | 72 | 0.080 |
Why?
|
| Medication Adherence | 2 | 2018 | 2165 | 0.080 |
Why?
|
| Physicians | 2 | 2023 | 4591 | 0.080 |
Why?
|
| Bradycardia | 1 | 2010 | 299 | 0.080 |
Why?
|
| Pain | 3 | 2022 | 5066 | 0.080 |
Why?
|
| Earthquakes | 1 | 2011 | 186 | 0.080 |
Why?
|
| Receptors, Leptin | 1 | 2010 | 350 | 0.080 |
Why?
|
| Inpatients | 1 | 2020 | 2581 | 0.080 |
Why?
|
| Peroxidase | 1 | 2011 | 605 | 0.080 |
Why?
|
| Cecum | 1 | 2009 | 232 | 0.080 |
Why?
|
| Syndrome | 3 | 2022 | 3280 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 1557 | 0.080 |
Why?
|
| Dehydration | 1 | 2009 | 216 | 0.080 |
Why?
|
| Ligation | 1 | 2009 | 448 | 0.080 |
Why?
|
| Physical Fitness | 1 | 2012 | 732 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 2852 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 10344 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 875 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 6538 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 2138 | 0.070 |
Why?
|
| Environmental Monitoring | 2 | 2011 | 1441 | 0.070 |
Why?
|
| Asthma | 2 | 2018 | 6172 | 0.070 |
Why?
|
| Microvessels | 1 | 2012 | 572 | 0.070 |
Why?
|
| Thrombomodulin | 2 | 2019 | 105 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1602 | 0.070 |
Why?
|
| Environmental Exposure | 2 | 2020 | 4412 | 0.070 |
Why?
|
| Decision Making | 2 | 2012 | 3925 | 0.070 |
Why?
|
| Capnography | 1 | 2008 | 91 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 22023 | 0.070 |
Why?
|
| Phenotype | 4 | 2024 | 16546 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2013 | 1112 | 0.070 |
Why?
|
| Serpins | 1 | 2009 | 247 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2022 | 9287 | 0.070 |
Why?
|
| Central Venous Pressure | 3 | 2012 | 79 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 3880 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 858 | 0.070 |
Why?
|
| Metabolomics | 1 | 2016 | 1628 | 0.070 |
Why?
|
| Forecasting | 2 | 2011 | 2932 | 0.070 |
Why?
|
| Curriculum | 2 | 2019 | 3718 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 791 | 0.070 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 1096 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 145 | 0.070 |
Why?
|
| P-Selectin | 1 | 2009 | 599 | 0.070 |
Why?
|
| Communication | 2 | 2019 | 3849 | 0.070 |
Why?
|
| Monocytes | 2 | 2019 | 2575 | 0.070 |
Why?
|
| Adiponectin | 1 | 2012 | 1115 | 0.070 |
Why?
|
| Echocardiography | 2 | 2020 | 4981 | 0.070 |
Why?
|
| Extremities | 1 | 2011 | 867 | 0.070 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 726 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2282 | 0.070 |
Why?
|
| Knowledge | 1 | 2007 | 176 | 0.060 |
Why?
|
| Linear Models | 2 | 2014 | 5877 | 0.060 |
Why?
|
| Heart Failure | 3 | 2020 | 11847 | 0.060 |
Why?
|
| Jurkat Cells | 2 | 2019 | 736 | 0.060 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 694 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2018 | 5961 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2010 | 1697 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2013 | 1082 | 0.060 |
Why?
|
| New Jersey | 1 | 2005 | 291 | 0.060 |
Why?
|
| Sex Factors | 5 | 2011 | 10547 | 0.060 |
Why?
|
| Bacteria | 1 | 2016 | 2199 | 0.060 |
Why?
|
| Quality of Life | 3 | 2022 | 13308 | 0.060 |
Why?
|
| Disease Management | 1 | 2016 | 2514 | 0.060 |
Why?
|
| Risk | 5 | 2017 | 9631 | 0.060 |
Why?
|
| Physical Examination | 1 | 2011 | 1244 | 0.060 |
Why?
|
| Urea | 1 | 2007 | 446 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 1628 | 0.060 |
Why?
|
| Drug Utilization | 2 | 2016 | 1195 | 0.060 |
Why?
|
| Blood Transfusion | 2 | 2014 | 1328 | 0.060 |
Why?
|
| Artifacts | 1 | 2013 | 1898 | 0.060 |
Why?
|
| Calcium | 2 | 2016 | 5725 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 1112 | 0.060 |
Why?
|
| Medicago | 1 | 2023 | 3 | 0.060 |
Why?
|
| Child | 4 | 2022 | 79806 | 0.060 |
Why?
|
| Medicare | 1 | 2022 | 6786 | 0.060 |
Why?
|
| Mice | 9 | 2019 | 81208 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 5201 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 3201 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 3763 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 1489 | 0.060 |
Why?
|
| Cardiotonic Agents | 3 | 2014 | 546 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2011 | 888 | 0.060 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2005 | 125 | 0.060 |
Why?
|
| Databases, Factual | 6 | 2018 | 8035 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2019 | 12427 | 0.060 |
Why?
|
| Health Care Rationing | 1 | 2007 | 435 | 0.060 |
Why?
|
| Internship and Residency | 2 | 2018 | 5870 | 0.060 |
Why?
|
| Cognition | 1 | 2021 | 6957 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 640 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 3448 | 0.050 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 907 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 167 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 1407 | 0.050 |
Why?
|
| Ambulances | 1 | 2003 | 92 | 0.050 |
Why?
|
| Registries | 3 | 2017 | 8469 | 0.050 |
Why?
|
| Neutrophils | 1 | 2015 | 3767 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2722 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 4353 | 0.050 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2009 | 793 | 0.050 |
Why?
|
| Perfusion | 1 | 2007 | 1376 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2012 | 6360 | 0.050 |
Why?
|
| Animals | 12 | 2019 | 167963 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 1683 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 730 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 1287 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 978 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2019 | 1190 | 0.050 |
Why?
|
| Delirium | 1 | 2014 | 1663 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2013 | 4563 | 0.050 |
Why?
|
| Masks | 1 | 2024 | 209 | 0.050 |
Why?
|
| Pulse Therapy, Drug | 1 | 2021 | 36 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2017 | 418 | 0.050 |
Why?
|
| Sulfonic Acids | 1 | 2021 | 102 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 3620 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2014 | 11891 | 0.050 |
Why?
|
| Catheterization | 1 | 2006 | 1432 | 0.050 |
Why?
|
| Self Report | 2 | 2023 | 3711 | 0.050 |
Why?
|
| Workload | 1 | 2007 | 847 | 0.050 |
Why?
|
| Massachusetts | 3 | 2014 | 8803 | 0.050 |
Why?
|
| Annual Reports as Topic | 1 | 2020 | 36 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2022 | 224 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2022 | 2326 | 0.050 |
Why?
|
| Fecal Impaction | 1 | 2020 | 32 | 0.050 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2012 | 3112 | 0.050 |
Why?
|
| Causality | 1 | 2007 | 1242 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2022 | 728 | 0.040 |
Why?
|
| Platelet Count | 1 | 2003 | 777 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 26951 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 25942 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 2164 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2020 | 105 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 861 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2020 | 238 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 5130 | 0.040 |
Why?
|
| Intubation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2015 | 707 | 0.040 |
Why?
|
| Heart Rate | 2 | 2009 | 4179 | 0.040 |
Why?
|
| Angiopoietin-1 | 1 | 2019 | 122 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 3150 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 12914 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5649 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 394 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 312 | 0.040 |
Why?
|
| Absenteeism | 1 | 2020 | 250 | 0.040 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2019 | 72 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2005 | 1949 | 0.040 |
Why?
|
| Algorithms | 2 | 2011 | 13981 | 0.040 |
Why?
|
| Immunization | 1 | 2023 | 1227 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2011 | 3047 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 257 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 482 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 616 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2010 | 3600 | 0.040 |
Why?
|
| International Cooperation | 1 | 2005 | 1433 | 0.040 |
Why?
|
| Urban Population | 1 | 2006 | 2022 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2007 | 6238 | 0.040 |
Why?
|
| Mortality | 2 | 2024 | 2916 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2021 | 3528 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2014 | 3258 | 0.040 |
Why?
|
| Heparitin Sulfate | 1 | 2019 | 224 | 0.040 |
Why?
|
| Consciousness Disorders | 1 | 2003 | 440 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 613 | 0.040 |
Why?
|
| Video Recording | 1 | 2023 | 955 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 1400 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 1055 | 0.040 |
Why?
|
| Cause of Death | 1 | 2008 | 3725 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2018 | 42063 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5794 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 981 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 379 | 0.040 |
Why?
|
| Manikins | 1 | 1999 | 242 | 0.040 |
Why?
|
| Isoprostanes | 1 | 2017 | 19 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 458 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2019 | 14372 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 587 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 4371 | 0.040 |
Why?
|
| Tumor Necrosis Factors | 1 | 2017 | 106 | 0.040 |
Why?
|
| Biopsy | 1 | 2009 | 6771 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2017 | 129 | 0.030 |
Why?
|
| Patient Simulation | 1 | 1999 | 297 | 0.030 |
Why?
|
| Acidosis | 1 | 2018 | 268 | 0.030 |
Why?
|
| Maltose-Binding Proteins | 1 | 2016 | 62 | 0.030 |
Why?
|
| New England | 1 | 2019 | 1050 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2019 | 698 | 0.030 |
Why?
|
| Ketorolac Tromethamine | 1 | 2016 | 21 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 857 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 3224 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2021 | 1069 | 0.030 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 1266 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 3455 | 0.030 |
Why?
|
| Exercise | 1 | 2012 | 5787 | 0.030 |
Why?
|
| Feedback | 1 | 2019 | 791 | 0.030 |
Why?
|
| Nausea | 1 | 2019 | 678 | 0.030 |
Why?
|
| Sheep | 1 | 2018 | 1441 | 0.030 |
Why?
|
| Documentation | 1 | 2022 | 893 | 0.030 |
Why?
|
| Suramin | 1 | 2015 | 34 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2021 | 3323 | 0.030 |
Why?
|
| Health Facilities | 1 | 2021 | 578 | 0.030 |
Why?
|
| Ventilators, Mechanical | 1 | 2018 | 287 | 0.030 |
Why?
|
| Blood Cells | 1 | 2017 | 305 | 0.030 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2016 | 150 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1998 | 377 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1998 | 987 | 0.030 |
Why?
|
| Aftercare | 1 | 2021 | 916 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2010 | 3426 | 0.030 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2014 | 22 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2023 | 2838 | 0.030 |
Why?
|
| Permeability | 1 | 2017 | 719 | 0.030 |
Why?
|
| Body Weight | 1 | 2005 | 4611 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 662 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 18137 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 570 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 242 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2016 | 303 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2010 | 18957 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2019 | 613 | 0.030 |
Why?
|
| Erythrocyte Membrane | 1 | 2016 | 439 | 0.030 |
Why?
|
| Complement C3b | 1 | 2014 | 99 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 464 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2016 | 471 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 484 | 0.030 |
Why?
|
| Viral Load | 1 | 2023 | 3322 | 0.030 |
Why?
|
| Hemostasis | 1 | 2017 | 468 | 0.030 |
Why?
|
| Observation | 1 | 2015 | 312 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2017 | 623 | 0.030 |
Why?
|
| Antimalarials | 1 | 2020 | 906 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2014 | 169 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 731 | 0.030 |
Why?
|
| Medical Audit | 1 | 2015 | 452 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2017 | 980 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16939 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 314 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 296 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2013 | 6796 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 251 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2021 | 1182 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2016 | 805 | 0.030 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 2012 | 13 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 1850 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 885 | 0.030 |
Why?
|
| Tachycardia | 1 | 2015 | 602 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1447 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 495 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2192 | 0.020 |
Why?
|
| Time | 1 | 2014 | 545 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2013 | 516 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2019 | 1889 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 372 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 15757 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2018 | 3094 | 0.020 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2012 | 132 | 0.020 |
Why?
|
| Health Behavior | 2 | 2014 | 2622 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 12922 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 9962 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1175 | 0.020 |
Why?
|
| Emergency Nursing | 1 | 2011 | 42 | 0.020 |
Why?
|
| Cross Infection | 1 | 2020 | 1434 | 0.020 |
Why?
|
| Blood Component Removal | 1 | 2012 | 132 | 0.020 |
Why?
|
| Myocardium | 1 | 2003 | 4700 | 0.020 |
Why?
|
| Siberia | 1 | 2010 | 30 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2017 | 2362 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 565 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 687 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4899 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 555 | 0.020 |
Why?
|
| Dobutamine | 1 | 2010 | 116 | 0.020 |
Why?
|
| Health Personnel | 1 | 2023 | 3310 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2222 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2013 | 768 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2013 | 926 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2022 | 3061 | 0.020 |
Why?
|
| Vibration | 1 | 2011 | 327 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 2420 | 0.020 |
Why?
|
| General Surgery | 1 | 2020 | 1678 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2011 | 280 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2018 | 1801 | 0.020 |
Why?
|
| Myoglobin | 1 | 2009 | 159 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3928 | 0.020 |
Why?
|
| Demography | 1 | 2014 | 1650 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7588 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2557 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 211 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1673 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3905 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2020 | 2147 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10827 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 981 | 0.020 |
Why?
|
| Angiography | 1 | 2013 | 1605 | 0.020 |
Why?
|
| Survivors | 1 | 2019 | 2375 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 7021 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 14495 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 2010 | 365 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1999 | 2511 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 1326 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 1753 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2013 | 976 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1902 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3602 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 1818 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1157 | 0.020 |
Why?
|
| Palliative Care | 1 | 2022 | 3607 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9530 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 2363 | 0.020 |
Why?
|
| Students, Medical | 1 | 2019 | 1927 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2010 | 699 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 1047 | 0.020 |
Why?
|
| Swine | 1 | 2016 | 5899 | 0.020 |
Why?
|
| Electrocardiography | 2 | 2013 | 6414 | 0.020 |
Why?
|
| Vitamin D | 1 | 2019 | 3291 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3388 | 0.020 |
Why?
|
| Heterozygote | 1 | 2012 | 2798 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2023 | 4775 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6498 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 3841 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 748 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 4925 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2005 | 206 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2016 | 8313 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2013 | 2488 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2255 | 0.010 |
Why?
|
| Body Composition | 1 | 2013 | 2419 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 1023 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2016 | 4219 | 0.010 |
Why?
|
| Telemedicine | 1 | 2021 | 3018 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 988 | 0.010 |
Why?
|
| Health Services Research | 1 | 2010 | 1810 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 2128 | 0.010 |
Why?
|
| Lung | 1 | 2021 | 9994 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2013 | 1999 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 697 | 0.010 |
Why?
|
| Research Design | 1 | 2018 | 6180 | 0.010 |
Why?
|
| Research | 1 | 2010 | 1974 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 1190 | 0.010 |
Why?
|
| Reference Standards | 1 | 2005 | 1004 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8552 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2011 | 2062 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2003 | 691 | 0.010 |
Why?
|
| Unconsciousness | 1 | 2003 | 251 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2010 | 1155 | 0.010 |
Why?
|
| Pyridines | 1 | 2013 | 2879 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2005 | 664 | 0.010 |
Why?
|
| Rats | 1 | 2016 | 23711 | 0.010 |
Why?
|
| Wound Healing | 1 | 2010 | 2788 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 11071 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2006 | 2435 | 0.010 |
Why?
|
| Computational Biology | 1 | 2010 | 3505 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15697 | 0.010 |
Why?
|
| Kidney | 1 | 2013 | 7064 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3306 | 0.010 |
Why?
|
| Problem Solving | 1 | 1999 | 440 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15620 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 26181 | 0.010 |
Why?
|
| Interprofessional Relations | 1 | 1999 | 989 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2007 | 4360 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1999 | 3986 | 0.000 |
Why?
|